San Diego, California–(Newsfile Corp. – April 1, 2021) – Tryp Therapeutics Inc. (CSE: TRYP) (“ Tryp” or the “Company“), a pharmaceutical company focused on developing clinical-stage compounds for diseases with unmet medical needs, is pleased to announce that it has amended the terms of its stock option plan (the “Plan“) and granted stock options (the “Options“) to a director of the Company.


Previous articlePTSF53 – Psychedelics and Creativity, with Laura Dawn
Next articleICSS for Assessing the Abuse Potential of Psychedelics